99.2%
Wellness & Weightloss
Retatrutide (LY3437943)
Retatrutide (LY3437943) is a novel triple agonist targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. Developed by Eli Lilly, it represents the next generation of incretin-based metabolic therapeutics.
Purity
99.2%
Size
20mg
Price
$200
For research purposes only. Not for human consumption. Not a pharmaceutical product. Must be handled by qualified researchers in accordance with applicable regulations.
Research Data